10174382OCR.pdf (1.63 MB)
Breast cancer prognostication and screening kits and methods of using same
standard
posted on 2019-02-28, 00:00 authored by Steven Buechler, Sunil Badve, Yesim Gokmen-PolarA genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.
History
Patent Number
US 10174382 B2Other Application
14/711,566Inventor
Sunil Badve Steven Buechler Yesim Gokmen-PolarInventor from Local Institution
Steven BuechlerAssignee
University of Notre Dame Du Lac Indiana University Research and Technology Corporation (Indianapolis)Date Modified
2019-02-28Language
- English
Claims
5Prior Publication Number
US 20160333413 A1Publisher
U.S. Patent and Trademark OfficeCooperative Patent Classification Codes
C12Q 1/6886 (20130101); C12Q 2600/118 (20130101); C12Q 2600/158 (20130101)Contributor
Steven BuechlerInternational Patent Classification Codes
C12Q 1/68 (20180101); C07H 21/04 (20060101); C12Q 1/6886 (20180101)Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC